Celgene handed over $101 million in upfront monies to San Diego-based Vividion Therapeutics, Inc. as part of an agreement to develop small molecule therapies. Source: BioSpace

In its IPO announcement last week Unum revealed early data from its Phase I non-Hodgkin lymphoma therapy that included toxicity concerns at higher dosing levels. Source: BioSpace

Shares of Prometic Life Sciences Inc. jumped this morning after securing the U.S. Food and Drug Administration’s Rare Pediatric Disease Designation. Source: BioSpace

Vanda Pharmaceuticals announced positive results from its JET8 Phase III clinical trial of Hetlioz for jet lag disorder. Source: BioSpace

Dermira plans to shutter the program and move on to more promising compounds. Source: BioSpace

A mid-stage program aimed at treating myelosuppression in lung cancer patients undergoing chemotherapy is yielding positive results. Source: BioSpace

A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe. Source: BioSpace

OPKO Health’s fourth-quarter report highlighted positive activities in the face of a net loss of $213.9 million during the most recent quarter. Source: BioSpace

Figuring out the best way to turn down a job offer is a “good” problem to have. If anything, receiving one or multiple job offers gives you a sense of…

The U.S. Food and Drug Administration (FDA) issued new draft guidance for preclinical trials in Alzheimer’s. Source: BioSpace